» Articles » PMID: 32377395

Regulation of TFEB Activity and Its Potential As a Therapeutic Target Against Kidney Diseases

Overview
Date 2020 May 8
PMID 32377395
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor EB (TFEB) regulates the expression of target genes bearing the Coordinated Lysosomal Expression and Regulation (CLEAR) motif, thereby modulating autophagy and lysosomal biogenesis. Furthermore, TFEB can bind to the promoter of autophagy-associated genes and induce the formation of autophagosomes, autophagosome-lysosome fusion, and lysosomal cargo degradation. An increasing number of studies have shown that TFEB stimulates the intracellular clearance of pathogenic factors by enhancing autophagy and lysosomal function in multiple kidney diseases, such as cystinosis, acute kidney injury, and diabetic nephropathy. Taken together, this highlights the importance of developing novel therapeutic strategies against kidney diseases based on TFEB regulation. In this review, we present an overview of the current data on TFEB and its implication in kidney disease.

Citing Articles

Neuropeptide S and its receptor aggravated asthma via TFEB dependent autophagy in bronchial epithelial cells.

Wang Z, Zhao P, Yan G, Sun A, Xu L, Li J Respir Res. 2025; 26(1):50.

PMID: 39930427 PMC: 11812264. DOI: 10.1186/s12931-025-03125-9.


Obesity modulates NK cell activity via LDL and DUSP1 signaling for populations with adverse social determinants.

Baumer Y, Singh K, Saurabh A, Baez A, Gutierrez-Huerta C, Chen L JCI Insight. 2024; 10(2).

PMID: 39718832 PMC: 11790026. DOI: 10.1172/jci.insight.180606.


The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB.

Losby M, Hayes M, Valfort A, Sopariwala D, Sanders R, Walker J Mol Pharmacol. 2024; 106(4):164-172.

PMID: 39168657 PMC: 11413914. DOI: 10.1124/molpharm.124.000889.


TXNIP deficiency attenuates renal fibrosis by modulating mTORC1/TFEB-mediated autophagy in diabetic kidney disease.

Du Y, Wu M, Song S, Bian Y, Shi Y Ren Fail. 2024; 46(1):2338933.

PMID: 38616177 PMC: 11018024. DOI: 10.1080/0886022X.2024.2338933.


From the regulatory mechanism of TFEB to its therapeutic implications.

Chen H, Gong S, Zhang H, Chen Y, Liu Y, Hao J Cell Death Discov. 2024; 10(1):84.

PMID: 38365838 PMC: 10873368. DOI: 10.1038/s41420-024-01850-6.


References
1.
Noh H, King G . The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl. 2007; (106):S49-53. DOI: 10.1038/sj.ki.5002386. View

2.
Pastore N, Blomenkamp K, Annunziata F, Piccolo P, Mithbaokar P, Sepe R . Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency. EMBO Mol Med. 2013; 5(3):397-412. PMC: 3598080. DOI: 10.1002/emmm.201202046. View

3.
Pabla N, Dong Z . Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73(9):994-1007. DOI: 10.1038/sj.ki.5002786. View

4.
Kauffman E, Ricketts C, Rais-Bahrami S, Yang Y, Merino M, Bottaro D . Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014; 11(8):465-75. PMC: 4551450. DOI: 10.1038/nrurol.2014.162. View

5.
Zhao G, Zhao Q, Zhou X, Mattei M, de Crombrugghe B . TFEC, a basic helix-loop-helix protein, forms heterodimers with TFE3 and inhibits TFE3-dependent transcription activation. Mol Cell Biol. 1993; 13(8):4505-12. PMC: 360062. DOI: 10.1128/mcb.13.8.4505-4512.1993. View